Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. - Wikidata - wikimedia - TriplyDB

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

http://www.wikidata.org/entity/Q33418712

about

Current Trends of Renal Impairment in Multiple Myeloma Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.IMiDs for myeloma induced renal impairment

P2860

Q26740444-EDA66EE6-02AA-437F-A36C-D9FCC3DE12B2 Q36351120-9D29B57C-B74C-4D9A-80BF-6C12A94BA1D5 Q38413040-A65900F3-85DE-4AFA-88BC-A806CD4604FE Q38896793-2D92561C-E48C-4637-96A3-DA1C7C2F911C Q38900024-FC93BA7E-9234-4FC6-8EC7-B87EF2D98D95 Q38959138-F8AE34E8-E422-4E83-9056-6A33430FD5CA Q38976968-6FB732EC-5402-417C-94A1-16BEEE456998 Q40299548-C3D46CBC-9932-4B63-8EBA-7BA791E0D208 Q53173592-C1C7F27F-938E-4268-9980-20EAC8596941 Q59135005-292ED397-5B1D-4156-9375-DE0E3EF8099F

P2860

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

http://www.wikidata.org/entity/Q33418712

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@ast

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@en

type

label

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@ast

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@en

prefLabel

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@ast

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@en

P1433

Q33418712-E32F9121-1DF7-4A97-BC76-66C28B51F296

P1476

Q33418712-7798A5AE-398F-49B4-B233-15B7474FCC4D

P2093

Q33418712-0C2030F5-6017-47F2-ABF4-FAC868C25AE1

Q33418712-0CECFC55-AFB6-49DA-A5B8-0DA0DC26E819

Q33418712-352AA76F-1DFC-47EF-9CB5-A0C84B753A6C

Q33418712-526608FF-7EE8-465F-B7E4-A3D7E216B98B

Q33418712-542603E6-A518-44EA-9F97-9F0C67BEECC2

Q33418712-64017B1F-0FC3-47DD-8EB4-7233B3F3D230

Q33418712-91ED59C3-DBF6-465C-A73C-B15E79CCD486

Q33418712-9B8FDF40-CCAD-4FF9-955B-FAE0049F9CF9

Q33418712-BD03D757-F807-4734-B9F2-4F8C767EC663

Q33418712-DF4CC017-40E1-4798-B2A9-1A12CCF99E81

P2860

Q33418712-1E6AF9BF-D3FB-4011-831F-061D746BAC15

Q33418712-276D03FC-D542-42DD-97AC-BE7D679DC518

Q33418712-3E16FAC2-EE15-4103-98C8-171484307B70

Q33418712-434B38E8-33AC-44BA-A4B3-B74DEE1AD3DE

Q33418712-4AD4B66F-3E49-46A3-90A0-27BD8D681908

Q33418712-4BD2585A-89CF-4E9F-BD1E-0AA5A909CC87

Q33418712-4EC9678D-690F-45B6-80FD-9BACF0DF970F

Q33418712-4FBE6CC3-DFF9-41C3-9D76-A5D0AD02E910

Q33418712-70CEA14B-E09D-4CF2-AC54-4406E6B4D006

Q33418712-7B4CD45C-2F93-4DED-AB34-AF2E2793AE45

P304

Q33418712-A25C25E5-73E7-450E-806B-393A1D98F878

P31

Q33418712-F219A7B9-7F45-44F8-9A96-D4C727DDFA55

P356

Q33418712-1838B3A0-5FD2-44FC-8CEC-8AD3301C59E2

P433

Q33418712-570EBF7D-0215-40BE-8C86-379CEF9F50FE

P478

Q33418712-0DA33F27-E749-40AA-BAFF-585EBD3E72F5

P50

Q33418712-669D0755-FE1A-4209-A274-1DCF55BEDAC7

P577

Q33418712-6161E0E3-2B4D-4072-8DF5-B1C2F1239D66

P5875

Q33418712-FE477CCC-1959-4FA6-82BB-C7EC5799BAA9

P698

Q33418712-5DA5AF0E-31C4-464A-90DD-CEB77C6DBF55

P921

Q33418712-64AC2EB6-208F-4C50-9A47-E834ACD84D77

P932

Q33418712-FB5B466D-FD6A-4612-BE5A-9443978C1C36

P356

HAEMATOL.2014.115204

P1433

P1476

Lenalidomide and dexamethasone ...... nal failure: a phase II study.

@en

P2093

Adalbert Weißmann

http://www.w3.org/2001/XMLSchema#string

Daniel Heintel

http://www.w3.org/2001/XMLSchema#string

Elisabeth Rauch

http://www.w3.org/2001/XMLSchema#string

Ercan Müldür

http://www.w3.org/2001/XMLSchema#string

Eva-Maria Autzinger

http://www.w3.org/2001/XMLSchema#string

Hedwig Kasparu

http://www.w3.org/2001/XMLSchema#string

Niklas Zojer

http://www.w3.org/2001/XMLSchema#string

Richard Greil

http://www.w3.org/2001/XMLSchema#string

Thomas Kuehr

http://www.w3.org/2001/XMLSchema#string

Wolfram Poenisch

http://www.w3.org/2001/XMLSchema#string

P2860

Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein

Prediction of creatinine clearance from serum creatinine

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

International uniform response criteria for multiple myeloma.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

P304

385-391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2014.115204

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268392358

http://www.w3.org/2001/XMLSchema#string

P698

25398836

http://www.w3.org/2001/XMLSchema#string

P921

P932

4349278

http://www.w3.org/2001/XMLSchema#string